Research programme: tyrosine kinase inhibitors - Roche
Alternative Names: 380317Latest Information Update: 16 Jul 2016
At a glance
- Originator Roche
- Class Pyrimidines; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Fibroblast growth factor inhibitors; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 02 Oct 2006 Preclinical data presented at the 232nd American Chemical Society National Meeting (232nd-ACS-2006) have been added to the pharmacokinetics and Cancer pharmacodynamics sections
- 22 Apr 2004 Preclinical trials in Cancer in USA (PO)